Clinical trials: Skin Carcinoma
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Breast Cancer, Non-small Cell Lung Cancer
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
This study was a randomized, single dose crossover comparison of the investigational product with a Reference Product (vinorelbine tartrate injection, NAVELBINE®).
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkins Lymphoma
- Trial name
- NCT00432562
- Testing
- Vinorelbine Tartrate
- Where
- 5 sites in Argentina
- Volunteers
- 31 people
- Sponsor
- Mast Therapeutics, Inc.
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the…
- Trial name
- NCT04137900
- Testing
- TAB004, Toripalimab
- Where
- 24 sites in United States
- Volunteers
- 499 people
- Sponsor
- TopAlliance Biosciences
Ovarian Carcinoma, Fallopian Tube Cancer
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
- Trial name
- NCT01091428
- Testing
- Alisertib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 191 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Cancer, Metastatic Colorectal Cancer
Study of OB-002 in Patients With Refractory Metastatic Cancer
This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two…
- Conditions
- Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- NCT05940844
- Testing
- OB-002
- Sponsor
- Orion Biotechnology Polska Sp. z o.o.
Endometrial Cancer, Ovarian Cancer
PRO1107 in Patients With Advanced Solid Tumors
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors.
- Conditions
- Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer
- Trial name
- NCT06171789
- Testing
- GEN1107
- Where
- 7 sites in United States, China
- Volunteers
- 33 people
- Sponsor
- Genmab
Neoplasms
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02122146
- Testing
- PF-06664178
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line.
- Conditions
- Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
- Trial name
- NCT05627960
- Testing
- AG-01 Compound
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- A&G Pharmaceutical Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Advanced Malignancies
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies.
- Trial name
- NCT05577182
- Testing
- INCA32459-101
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 46 people
- Sponsor
- Incyte Corporation
Solid Tumor, HER-2 Protein Overexpression
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting…
- Trial name
- NCT03680560
- Testing
- ACTR T Cell Product, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cogent Biosciences, Inc.
Breast Cancer
Breast Cancer Detection in Breast Surgical Specimens With the Histolog Scanner, Slide-free Confocal Microscope
Study to assess the capability of physicians (breast surgeons and pathologists) to recognize breast cancer in images of fresh lumpectomies generated with the Histolog Scanner, a recent large field-of-view confocal laser scanning…
- Trial name
- Hibiscuss (NCT04976556)
- Testing
- Histolog Scanner
- Where
- France
- Volunteers
- 181 people
- Sponsor
- SamanTree Medical SA
Imaging, Colorectal Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor…
- Conditions
- Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
- Trial name
- DUNP19 (NCT07272642)
- Testing
- LNTH-2403
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Radiopharm Theranostics, Ltd
Solid Tumor, Non Small Cell Lung Cancer
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT03343613
- Testing
- LY3381916, LY3300054
- Where
- 12 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04879849
- Testing
- Pembrolizumab, TAK-676, Image-guided radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Takeda
Melanoma, Non-small Cell Lung Cancer
A Study of IBI363 in Subjects with Advanced Solid Malignancies
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
- Trial name
- NCT06281678
- Testing
- IBI363
- Where
- 9 sites in United States
- Volunteers
- 178 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.